Comparison of GLP-1 analogues versus sitagliptin in the management of type 2 diabetes: systematic review and meta-analysis of head-to-head studies.
Level 1 - systematic review of randomized trials
Systematic review and meta-analysis of randomized controlled trials
PubMed 25089625 · doi:10.1371/journal.pone.0103798
What was done
Authors conducted a systematic review and meta-analysis of head-to-head randomized controlled trials comparing GLP-1 receptor agonists to sitagliptin in adults with type 2 diabetes. Continuous outcomes were evaluated as weighted mean differences (WMD) and dichotomous outcomes as relative risks (RR) using random-effects models with 95% confidence intervals.
What was found
Across 4 randomized trials with 1,755 patients, GLP-1 analogues showed significantly greater reductions in HbA1c (WMD -0.41%, 95% CI -0.51 to -0.31) and body weight (WMD -1.55 kg, 95% CI -1.98 to -1.12) compared to sitagliptin. GLP-1 analogues were associated with a significantly higher incidence of gastrointestinal adverse events: nausea (RR 3.14, 95% CI 2.15 to 4.59), vomiting (RR 2.60, 95% CI 1.48 to 4.56), diarrhea (RR 1.82, 95% CI 1.24 to 2.69), and constipation (RR 2.50, 95% CI 1.33 to 4.70). Blood pressure, lipid parameters, and hypoglycemia incidence were described as similar between groups, but no numerical values for these outcomes were reported in the abstract.
Why it matters
This meta-analysis clarifies the comparative trade-offs between two common second-line incretin classes, confirming that GLP-1 receptor agonists provide modest glycemic and weight benefits over sitagliptin at the cost of substantially higher gastrointestinal intolerance.
Limits
The analysis included only four head-to-head trials, limiting statistical power for subgroup evaluations and rare outcomes. The abstract does not specify the individual GLP-1 analogues studied, treatment durations, background therapies, or numerical data and heterogeneity values for blood pressure, lipids, and hypoglycemia.
Cited by
- supports Head-to-head clinical comparisons show that GLP-1 receptor agonists outperform Januvia (sitagliptin).